[144] Thermo Fisher Scientific, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for proposed sale of Thermo Fisher Scientific, Inc. (TMO) securities. The filer reports offering 295 shares of common stock through Fidelity Brokerage Services LLC with an aggregate market value of $147,512.35 and an approximate sale date of 08/20/2025. The filing lists 377,612,121 shares outstanding. The securities to be sold were acquired on 08/20/2025 by exercise of an option originally granted on 02/26/2019, and the payment method is indicated as cash. The filing also discloses securities sold during the past three months by Marc N. Casper totaling 18,201 shares for aggregate gross proceeds of $8,254,290.17. The notice includes the standard representation that the seller does not possess undisclosed material adverse information and contains the routine attestations required by Rule 144.

Positive

• Full disclosure of planned sale details including broker, shares, aggregate market value and approximate sale date
• Acquisition details provided (option grant date 02/26/2019 and acquisition date 08/20/2025) and payment method (cash)
• History of recent insider sales disclosed with dates and gross proceeds, supporting transparency

Negative

• Insider sold 18,201 shares in the past three months for aggregate gross proceeds of $8,254,290.17, which may be viewed negatively by some investors
• Filing does not include a signature or explicit plan adoption date in the provided content

Insights

Securities Analyst

TL;DR: Insider sale disclosed; small indicated planned sale (295 shares) and prior three-month insider sales totaling 18,201 shares.

The filing transparently reports a proposed sale of 295 common shares via Fidelity with an aggregate market value of $147,512.35 and confirms acquisition by option exercise dated 02/26/2019 and paid in cash. The historical sales table shows Marc N. Casper sold 10,000, 8,000 and 201 shares on 08/06/2025, 08/07/2025 and 08/19/2025 respectively, generating $8,254,290.17 in gross proceeds. From a market-impact perspective, the specific proposed sale size is explicitly stated; materiality relative to total outstanding shares should be evaluated with broader market data not included in this filing.

Compliance Officer

TL;DR: Filing meets Rule 144 disclosure elements; includes acquisition detail, broker, sale timing and past three-month sales.

The Form 144 includes required elements: broker name and address, number of shares to be sold, aggregate market value, acquisition details (option grant date and exercise/acquisition date), payment method, and prior three-month sales by the same person. The filing also contains the standard seller representation about lack of undisclosed material adverse information and the statutory warning regarding false statements. No signatures or plan adoption dates are provided in the visible content.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	295	147512.35	377612121	08/20/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/20/2025	Option Granted - 02/26/2019	Issuer			295	08/20/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/06/2025	10000	4518207.00
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/07/2025	8000	3635549.60
Marc N. Casper 168 Third Avenue Waltham MA 02451	Common	08/19/2025	201	100533.57

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Form 144 for TMO propose to sell?

The notice proposes to sell 295 shares of Thermo Fisher Scientific common stock through Fidelity Brokerage Services LLC with an aggregate market value of $147,512.35 and an approximate sale date of 08/20/2025.

How and when were the securities being sold acquired?

The securities were acquired on 08/20/2025 by exercise of an option that was granted on 02/26/2019, and the payment method is listed as cash.

Has the seller made other sales recently?

Yes. Marc N. Casper sold 10,000 shares on 08/06/2025, 8,000 shares on 08/07/2025, and 201 shares on 08/19/2025, totaling 18,201 shares for $8,254,290.17 in gross proceeds.

Which broker is handling the proposed sale?

The broker named is Fidelity Brokerage Services LLC located at 900 Salem Street, Smithfield, RI 02917.

Does the filing state whether the seller has undisclosed material information?

The filing includes the seller's representation that they do not know any material adverse information about the issuer that has not been publicly disclosed.